Stryker Corporation $SYK Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 12.0% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 933,161 shares of the medical technology company’s stock after buying an additional 99,996 shares during the period. Dimensional Fund Advisors LP’s holdings in Stryker were worth $344,962,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Laffer Tengler Investments Inc. boosted its position in shares of Stryker by 20.0% in the third quarter. Laffer Tengler Investments Inc. now owns 6,399 shares of the medical technology company’s stock worth $2,366,000 after buying an additional 1,065 shares during the period. Insigneo Advisory Services LLC boosted its holdings in Stryker by 15.5% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,409 shares of the medical technology company’s stock worth $521,000 after acquiring an additional 189 shares during the period. Great Lakes Retirement Inc. grew its position in Stryker by 2.2% in the third quarter. Great Lakes Retirement Inc. now owns 5,381 shares of the medical technology company’s stock valued at $1,989,000 after acquiring an additional 117 shares in the last quarter. Evernest Financial Advisors LLC raised its stake in shares of Stryker by 1.2% during the third quarter. Evernest Financial Advisors LLC now owns 3,920 shares of the medical technology company’s stock valued at $1,449,000 after purchasing an additional 46 shares during the period. Finally, Fiduciary Group LLC lifted its position in shares of Stryker by 0.7% during the third quarter. Fiduciary Group LLC now owns 4,416 shares of the medical technology company’s stock worth $1,632,000 after purchasing an additional 32 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of SYK stock opened at $370.07 on Friday. The stock has a market capitalization of $141.62 billion, a price-to-earnings ratio of 44.06, a PEG ratio of 2.23 and a beta of 0.85. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87. The company’s 50-day simple moving average is $365.25 and its 200-day simple moving average is $369.27. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period in the previous year, the company earned $4.01 earnings per share. Stryker’s quarterly revenue was up 11.4% on a year-over-year basis. Equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SYK shares. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target for the company in a report on Friday, December 19th. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a research report on Tuesday, January 6th. Wells Fargo & Company lifted their target price on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Needham & Company LLC boosted their price target on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Finally, Citigroup restated a “market outperform” rating on shares of Stryker in a research note on Friday, January 30th. Fourteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and an average target price of $428.61.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.